- Home
- LSF vs ADAG Comparison
LSF vs ADAG Comparison
Compare LSF & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- ADAG
- Stock Information
- Founded
- LSF 2015
- ADAG 2011
- Country
- LSF United States
- ADAG China
- Employees
- LSF N/A
- ADAG N/A
- Industry
- LSF Packaged Foods
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- ADAG Health Care
- Exchange
- LSF Nasdaq
- ADAG Nasdaq
- Market Cap
- LSF 71.7M
- ADAG 85.9M
- IPO Year
- LSF 2020
- ADAG 2021
- Fundamental
- Price
- LSF $6.86
- ADAG $1.84
- Analyst Decision
- LSF Strong Buy
- ADAG Strong Buy
- Analyst Count
- LSF 2
- ADAG 1
- Target Price
- LSF $7.75
- ADAG $5.00
- AVG Volume (30 Days)
- LSF 71.9K
- ADAG 24.0K
- Earning Date
- LSF 03-11-2025
- ADAG 03-09-2025
- Dividend Yield
- LSF N/A
- ADAG N/A
- EPS Growth
- LSF N/A
- ADAG N/A
- EPS
- LSF N/A
- ADAG N/A
- Revenue
- LSF $40,896,326.00
- ADAG $815,746.00
- Revenue This Year
- LSF $27.95
- ADAG N/A
- Revenue Next Year
- LSF $21.07
- ADAG $2.70
- P/E Ratio
- LSF N/A
- ADAG N/A
- Revenue Growth
- LSF 20.33
- ADAG N/A
- 52 Week Low
- LSF $0.71
- ADAG $1.74
- 52 Week High
- LSF $10.90
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- LSF 39.97
- ADAG 40.33
- Support Level
- LSF $6.51
- ADAG $1.76
- Resistance Level
- LSF $7.59
- ADAG $2.07
- Average True Range (ATR)
- LSF 0.59
- ADAG 0.14
- MACD
- LSF -0.06
- ADAG -0.00
- Stochastic Oscillator
- LSF 16.43
- ADAG 23.53
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.